475 related articles for article (PubMed ID: 23210765)
1. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
Kasichayanula S; Liu X; Lacreta F; Griffen SC; Boulton DW
Clin Pharmacokinet; 2014 Jan; 53(1):17-27. PubMed ID: 24105299
[TBL] [Abstract][Full Text] [Related]
4. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.
Kasichayanula S; Liu X; Zhang W; Pfister M; LaCreta FP; Boulton DW
Clin Ther; 2011 Nov; 33(11):1798-808. PubMed ID: 22030444
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
Kasichayanula S; Chang M; Hasegawa M; Liu X; Yamahira N; LaCreta FP; Imai Y; Boulton DW
Diabetes Obes Metab; 2011 Apr; 13(4):357-65. PubMed ID: 21226818
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
Watada H; Shiramoto M; Ueda S; Tang W; Asano M; Thorén F; Kim H; Yajima T; Boulton DW; Araki E
Diabetes Obes Metab; 2019 Apr; 21(4):876-882. PubMed ID: 30499157
[TBL] [Abstract][Full Text] [Related]
8. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
[TBL] [Abstract][Full Text] [Related]
9. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.
Kasichayanula S; Liu X; Griffen SC; Lacreta FP; Boulton DW
Diabetes Obes Metab; 2013 Mar; 15(3):280-3. PubMed ID: 23061428
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
11. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjects.
Tang W; Reele S; Hamer-Maansson JE; Parikh S; de Bruin TW
Diabetes Obes Metab; 2015 Apr; 17(4):423-5. PubMed ID: 25511685
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
Komoroski B; Vachharajani N; Boulton D; Kornhauser D; Geraldes M; Li L; Pfister M
Clin Pharmacol Ther; 2009 May; 85(5):520-6. PubMed ID: 19129748
[TBL] [Abstract][Full Text] [Related]
14. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
Demaris KM; White JR
Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.
Tang W; Leil TA; Johnsson E; Boulton DW; LaCreta F
Diabetes Obes Metab; 2016 Mar; 18(3):236-40. PubMed ID: 26510924
[TBL] [Abstract][Full Text] [Related]
17. Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes.
Nakamura Y; Nagai Y; Terashima Y; Nishine A; Ishii S; Kato H; Ohta A; Tanaka Y
Expert Opin Pharmacother; 2015; 16(17):2553-9. PubMed ID: 26479189
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
Calado J
IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
[TBL] [Abstract][Full Text] [Related]
19. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
Albarrán OG; Ampudia-Blasco FJ
Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
[TBL] [Abstract][Full Text] [Related]
20. Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial.
Hallow KM; Boulton DW; Penland RC; Helmlinger G; Nieves EH; van Raalte DH; Heerspink HL; Greasley PJ
J Pharmacol Exp Ther; 2020 Oct; 375(1):76-91. PubMed ID: 32764153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]